[go: up one dir, main page]

GB201819430D0 - Therapeutic compounds, nanoparticles and uses thereof - Google Patents

Therapeutic compounds, nanoparticles and uses thereof

Info

Publication number
GB201819430D0
GB201819430D0 GBGB1819430.8A GB201819430A GB201819430D0 GB 201819430 D0 GB201819430 D0 GB 201819430D0 GB 201819430 A GB201819430 A GB 201819430A GB 201819430 D0 GB201819430 D0 GB 201819430D0
Authority
GB
United Kingdom
Prior art keywords
nanoparticles
therapeutic compounds
therapeutic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1819430.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midatech Ltd
Original Assignee
Midatech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midatech Ltd filed Critical Midatech Ltd
Priority to GBGB1819430.8A priority Critical patent/GB201819430D0/en
Publication of GB201819430D0 publication Critical patent/GB201819430D0/en
Priority to PCT/EP2019/082810 priority patent/WO2020109428A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1819430.8A 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof Ceased GB201819430D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1819430.8A GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof
PCT/EP2019/082810 WO2020109428A1 (en) 2018-11-29 2019-11-27 Therapeutic compounds, nanoparticles and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1819430.8A GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof

Publications (1)

Publication Number Publication Date
GB201819430D0 true GB201819430D0 (en) 2019-01-16

Family

ID=65024711

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1819430.8A Ceased GB201819430D0 (en) 2018-11-29 2018-11-29 Therapeutic compounds, nanoparticles and uses thereof

Country Status (2)

Country Link
GB (1) GB201819430D0 (en)
WO (1) WO2020109428A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591386B (en) * 2022-05-10 2022-09-09 深圳厚存纳米药业有限公司 Uridine derivative-containing nanoparticle, nucleic acid nanocomposite and preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
JP2006500364A (en) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド Crosslinkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
ES2242528B1 (en) 2004-03-25 2006-12-01 Consejo Sup. Investig. Cientificas MAGNETIC NANOPARTICLES OF NOBLE METALS.
EP1756289B1 (en) 2004-05-24 2015-01-14 Midatech Ltd. Nanoparticles comprising rna ligands
WO2006037979A2 (en) 2004-10-01 2006-04-13 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
EP1919507A2 (en) 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
CA2652759C (en) 2006-04-13 2014-07-08 Midatech Limited Nanoparticles for providing immune responses against infectious agents
KR101105428B1 (en) 2009-02-12 2012-01-17 경북대학교 산학협력단 Peptides Specific to Glycocan-3 Proteins
US20120270238A1 (en) 2009-10-22 2012-10-25 Moro Ricardo J Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof
US9441002B2 (en) 2012-10-27 2016-09-13 Chemgenes Corporation Dithiolane based thiol modifier for labeling and stronger immobilization of bio-molecules on solid surfaces
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
US20160143914A1 (en) 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
WO2015061507A1 (en) 2013-10-23 2015-04-30 Chemgenes Corporation Dithiolane functionalized nucleoside amidites and supports for stronger immobilization of bio-molecules on solid surfaces
GB201420080D0 (en) * 2014-11-11 2014-12-24 Midatech Ltd And Q Chip Ltd Sustained release encapsulated nanoparticles
JP2018519283A (en) 2015-06-30 2018-07-19 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Targeted conjugates and their particles and formulations
US10688193B2 (en) 2015-07-22 2020-06-23 Gnt Biotech & Medicals Corporation PH-sensitive linkers for delivering a therapeutic agent
GB2541166A (en) * 2015-07-24 2017-02-15 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
GB201701745D0 (en) * 2017-02-02 2017-03-22 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging
CN107096038B (en) * 2017-04-12 2021-06-18 苏州大学 Preparation method of cross-linked nanomedicine based on active reaction type one-step method

Also Published As

Publication number Publication date
WO2020109428A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IL291922B1 (en) Fap-activated therapeutic agents, and uses related thereto
EP3720502A4 (en) Cytobiologics and therapeutic uses thereof
IL268469B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL272055A (en) 1,8-naphthyridinone compounds and uses thereof
IL276753A (en) Afibrotic compounds, devices, and uses thereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201715194D0 (en) Compounds and their therapeutic use
IL265269B (en) Novel compounds and therapeutic uses thereof
IL270460B1 (en) Novel compounds and therapeutic uses thereof
GB2579240B (en) New processes, compositions and medical uses
PL3501507T3 (en) Macrogols for application to the mucosa, and therapeutic uses thereof
GB201819430D0 (en) Therapeutic compounds, nanoparticles and uses thereof
HUE057090T2 (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
GB201818517D0 (en) Nanoparticles and uses thereof
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
HK40039258A (en) Cytobiologics and therapeutic uses thereof
AU2017905204A0 (en) Therapeutic Compounds and Uses Thereof
GB2558788B (en) New therapeutic uses
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB201705682D0 (en) Novel compounds and therapeutic uses thereof
GB201705681D0 (en) Novel compounds and therapeutic uses thereof
GB201705685D0 (en) Novel compounds and therapeutic uses thereof
GB201705687D0 (en) Novel compounds and therapeutic uses thereof
GB201705678D0 (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)